Sarepta Therapeutics (SRPT) Continues Run as Eteplirsen Sentiment Remains High
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Sarepta Therapeutics (SRPT) Riding High On Successful Drug
August 30, 2012 8:08 AM EDTSarepta Therapeutics, Inc. (Nasdaq: SRPT) is higher yet again in pre-open trading Thursday as the company's Duchenne Muscular Dystrophy treatment continues to get positive, tear-jerking press.
Yesterday evening,... More
Sarepta Therapeutics (SRPT) Higher on Barron's Mention
August 27, 2012 9:05 AM EDTSarepta Therapeutics (Nasdaq: SRPT) continues its recent ramp following a positive piece in Barron's over the weekend highlighting the company's treatment for Duchenne muscular dystrophy.
While shares are up from $4 to $10 recently, analysts argue they could go as high as $26 as peak sales of... More
